No insider purchase over the last 90 days. The latest, by Katz Avi S, was filed 23 Jan 2026.
QT Imaging Holdings, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 24 October 2026, brought 15 filings signed by 9 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €133k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 board member. At €133k, the purchase published on 23 January 2026 by Katz Avi S is the largest of the period.
The most recent open-market purchase was published on 23 January 2026, 274 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade.
Across the 3,169 companies tracked on its exchange, the median is 24 filings; at 15 filings, this issuer sits below that mark. Our records for QT Imaging Holdings, Inc. go back to 2023, with 13 purchases and 4 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 18.9 m USD and net income at -21.1 m USD.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
25 of 44 declarations
QT Imaging Holdings, Inc. is a NASDAQ-listed company specializing in the development of medical imaging technologies. It focuses on enhancing diagnostics and treatments through innovative solutions.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 18.9 m USD | -21.1 m USD | -2.01 USD | 10-K |
| Dec 2024 | 4.9 m USD | -9.0 m USD | -2.13 USD | 10-K |
| Dec 2023 | n.d. | -6.1 m USD | -0.64 USD | 10-K |
| Dec 2022 | n.d. | -2.8 m USD | -0.60 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.